Company: HURA
Filing Date: 2025-08-12
Form Type: S-1
Source: 0001193125-25-179009
Chunk: 307

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-08-12
Form: S-1
Chunk 307
---
     | December 31, 2023 |   |     |         |   |     |         |     |
|:----------------------------|:----|:------------------|:--|:----|:--------|:--|:----|:--------|----:|
| Liability                   |     | Level 1           |   |     | Level 2 |   |     | Level 3 |     |
| Milestone payment liability |     |                   | — |     |         | — |     |         | 179 |

| Balance - June 30, 2023       |     | $(in thousands) | 166 |
|:------------------------------|:----|:----------------|----:|
| Change in fair value estimate |     |                 |  13 |
| Balance - December 31, 2023   |     |                 | 179 |

The Company’s financial instruments consist of cash and cash equivalents, other receivables, accounts payable, and related party payables. The carrying values of cash and cash equivalents, other receivables, accounts payable and related party payables approximate their fair values due to the immediate or short-term maturity of these financial instruments.

| 10 | Subsequent events |

The Company has evaluated its subsequent events from December 31, 2023, through the date these condensed consolidated interim financial statements were issued and has determined that there are no subsequent events requiring disclosure in these condensed consolidated interim financial statements other than the items noted below.

<div align='center'>F-6 6</div>

Kintara Therapeutics, Inc. Notes to Condensed Consolidated Interim Financial Statements (Unaudited) December 31, 2023 (expressed in US dollars and in thousands, except par value and per share amounts, unless otherwise noted) Proceeds from the Company’s At-The-Market(“ ATM” ) facility From January 1, 2024 until February 12, 2024, the Company raised $ 6,108in net proceeds from the sale of 28,870shares of its common stock under the ATM Facility. Final CRO payment On January 9, 2024, the Company paid $ 400pursuant to the termination agreement with the CRO (Note 3). Initiation of REM-001Clinical Study On February 12, 2024, the Company announced the initiation of a REM-001 15-patientclinical trial in CMBC patients. Opt-OutNotice to Valent for VAL-083